Ameritas Investment Partners, Inc. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q1 2021$597,000
-18.6%
5,245
-0.9%
0.02%
-32.4%
Q4 2020$733,000
+81.9%
5,292
+8.0%
0.03%
+88.9%
Q3 2020$403,000
+2.8%
4,901
-2.2%
0.02%
-5.3%
Q2 2020$392,000
+81.5%
5,011
+3.2%
0.02%
+58.3%
Q1 2020$216,000
+9.1%
4,854
+4.5%
0.01%
+33.3%
Q4 2019$198,000
-0.5%
4,6460.0%0.01%0.0%
Q3 2019$199,000
-32.5%
4,6460.0%0.01%
-30.8%
Q2 2019$295,000
-2.3%
4,646
+6.7%
0.01%
-7.1%
Q1 2019$302,000
+75.6%
4,353
+10.1%
0.01%
+55.6%
Q4 2018$172,000
-43.0%
3,9530.0%0.01%
-35.7%
Q3 2018$302,000
-0.7%
3,9530.0%0.01%
-6.7%
Q2 2018$304,000
+58.3%
3,953
+5.1%
0.02%
+66.7%
Q1 2018$192,000
+19.3%
3,762
+8.3%
0.01%
+28.6%
Q4 2017$161,000
-18.7%
3,4740.0%0.01%
-22.2%
Q3 2017$198,000
-8.3%
3,4740.0%0.01%
-10.0%
Q2 2017$216,000
-1.4%
3,474
+7.7%
0.01%
-9.1%
Q1 2017$219,0000.0%3,226
+3.7%
0.01%0.0%
Q4 2016$219,000
-0.9%
3,1110.0%0.01%
-8.3%
Q3 2016$221,000
-34.8%
3,111
+3.0%
0.01%
-47.8%
Q4 2015$339,000
+16.5%
3,0210.0%0.02%
+9.5%
Q3 2015$291,000
+2.5%
3,021
+9.0%
0.02%
+10.5%
Q2 2015$284,0002,7710.02%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2018
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders